A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00774332
Recruitment Status : Unknown
Verified October 2008 by Cooperative Study Group A for Hematology. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
15 Years to 65 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with relapsed/resistant acute lymphoblastic leukemia
Patients must be between 15 and 65 years of age.
Estimated life expectancy of more than 3 months
ECOG performance status of 2 or lower, Karnofsky scale > 60 (see appendix I)
Adequate cardiac function (EF>45%) on echocardiogram or MUGA scan
Adequate kidney function (estimated Ccr >50 ml/min)
Patients with CNS involvement of leukemic blasts will not be excluded.
Patients with extramedullary relapse(s) only will be excluded.